title: A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.
abstract: Immunosuppression has recently been proposed for low-risk myelodysplastic syndromes (MDS) to reverse bone marrow failure by inhibiting intramedullary secretion of proapoptotic cytokines. We treated 35 MDS patients (24 refractory anaemia (RA), 10 RA with excess blasts and one chronic myelomonocytic leukaemia) with either horse antithymocyte globulin 15 mg/kg/day or rabbit antithymocyte globulin 3.75 mg/kg/day, each for 5 days. Median age was 63 years (range: 41-75). After 1 to 34+ months of follow-up (mean: 15+), four patients experienced complete haematological responses (CR), six good responses (GR) and two minor responses. All CRs and GRs occurred in patients with RA, in whom both horse and rabbit ATG yielded five responses out of 12 (42%). Time to response varied between 1 and 10 (mean: 3) months. The median duration of response was 9+ (1-17+) months; five patients are in continuing response. In all, 23 patients suffered side effects > degrees II WHO (the degree of toxicity encountered according to the internationally accepted WHO toxicity grading); one patient died 2 weeks after rabbit ATG from rhinocerebral mucormycosis. Parameters that correlated with response were duration of disease and RA subgroup. In our experience, immune-modulating therapy with either horse or rabbit ATG is feasible in patients with RA and short duration of disease.
authors.affiliation: Department of Haematology and Oncology, Medizinische Hochschule, Hannover, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Stadler
authors.forename: U
authors.initials: U
authors.lastname: Germing
authors.forename: K-O
authors.initials: KO
authors.lastname: Kliche
authors.forename: K M
authors.initials: KM
authors.lastname: Josten
authors.forename: R
authors.initials: R
authors.lastname: Kuse
authors.forename: W-K
authors.initials: WK
authors.lastname: Hofmann
authors.forename: H
authors.initials: H
authors.lastname: Schrezenmeier
authors.forename: J
authors.initials: J
authors.lastname: Novotny
authors.forename: O
authors.initials: O
authors.lastname: Anders
authors.forename: H
authors.initials: H
authors.lastname: Eimermacher
authors.forename: W
authors.initials: W
authors.lastname: Verbeek
authors.forename: H-H
authors.initials: HH
authors.lastname: Kreipe
authors.forename: H
authors.initials: H
authors.lastname: Heimpel
authors.forename: C
authors.initials: C
authors.lastname: Aul
authors.forename: A
authors.initials: A
authors.lastname: Ganser
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D005260:Female; D006736:Horses; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000276:immunology / Q000628:therapy*; D011446:Prospective Studies; D011817:Rabbits; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents